The global cell therapy technologies market is projected to reach USD 19.9 billion by 2023 from USD 10.2 billion in 2018, at a CAGR of 14.4% during the forecast period.
Factors such as rising government investments for cell-based research, the increasing number of GMP-certified production facilities, and the large number of oncology-oriented cell-based therapy clinical trials are driving the growth of this market.
China, India, Japan, Korea, and Brazil are emerging markets for cell therapy instruments. These markets boast comparatively lenient standards and government regulations as opposed to developed markets in North America and the EU, and thus offer significant growth potential for providers. However, the high cost of cell-based research and the low success rate is expected to restrain market growth to some extent during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21333497
The global cell therapy technologies market segmentation:
Key Market Players
Key players in this cell therapy technologies market include Beckman Coulter (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT (US), and Thermo Fisher Scientific (US).
Thermo Fisher was the largest player in the cell therapy technologies market in 2017. In order to maintain its position in the market and further expand its product portfolio, the company focuses on the strategies of product launches, acquisitions, and expansions. Merck holds the second position in the cell therapy technologies market. The company focuses on collaborations, agreements, and acquisitions to enhance its market position.
Geographical Detailed Analysis for the cell therapy instruments market :
The market, by region, is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of this market in 2018. The large share of this regional segment can primarily be attributed to the high burden of chronic diseases and increasing R&D activities in pharmaceutical and biotechnology industries.
The market is dominated by players such as Beckman Coulter, Inc. (US), Becton, Dickinson and Company (US), GE Healthcare (US), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT, Inc. (US), and Thermo Fisher Scientific, Inc. (US).
Read More in Detailed (cell therapy instruments market):